Magenta Therapeutics, Inc.
At Close: 4:00 PM
MGTA Stock Price Graph
MGTA Stock Price Today
Magenta Therapeutics, Inc. (MGTA) stock declined over -93.28% intraday to trade at $0.6996 a share on NASDAQ. The stock opened with a loss of -93.31% at $0.71 and touched an intraday high of $0.76, falling -93.39% against the last close of $10.59. The Magenta Therapeutics, Inc. in stock market went to a low of $0.69 during the session.
MGTA Stock Snapshot
Number of Shares
Cash Flow per Share
Free Float in %
MGTA Stock Price History Chart
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Frequently Asked Questions
What is the current Magenta Therapeutics, Inc. (MGTA) stock price?
Magenta Therapeutics, Inc. (NASDAQ: MGTA) stock price is $0.70 in the last trading session. During the trading session, MGTA stock reached the peak price of $0.76 while $0.69 was the lowest point it dropped to. The percentage change in MGTA stock occurred in the recent session was -93.28% while the dollar amount for the price change in MGTA stock was -$9.71.
MGTA's industry and sector of operation?
The NASDAQ listed MGTA is part of Biotechnology industry that operates in the broader Healthcare sector. Magenta Therapeutics, Inc. , a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases.
Who are the executives of MGTA?
Dr. Jason Gardner DPHIL, Ph.D.
Co-Founder, Chief Executive Officer, Pres & Director
Mr. Jim Haney
Senior Director of Investor Relations
Director of Corporation Communications
Dr. Jason Gardner DPHIL, Ph.D.
Co-Founder, CEO, Pres & Director
How MGTA did perform over past 52-week?
MGTA's closing price is 1.10% higher than its 52-week low of $0.321 where as its distance from 52-week high of $1.81 is -0.70%.
How many employees does MGTA have?
Number of MGTA employees currently stands at N/A. MGTA operates from 100 Technology Square, Cambridge, MA 02139, US.
Link for MGTA official website?
Official Website of MGTA is: https://www.magentatx.com
How do I contact MGTA?
How many shares of MGTA are traded daily?
MGTA stock volume for the day was 375912.00 shares. The average number of MGTA shares traded daily for last 3 months was 22.89 Thousands.
What is the market cap of MGTA currently?
The market value of MGTA currently stands at $140.79 Million with its latest stock price at $0.70 and N/A of its shares outstanding.